Top
Skip to Content
LOGO(small) - Queen's University Belfast
  • Our
  • Our
  • Our
  • Our
LOGO(large) - Queen's University Belfast

School of

Medicine, Dentistry & Biomedical Sciences

  • Home
  • Study
    • Postgraduate Taught
    • Postgraduate Research
    • Centre for Biomedical Sciences Education
    • Intercalated Degrees
    • Clinical Academic Training
  • Research
    • Research in the School of Medicine, Dentistry and Biomedical Sciences
    • Meet our Researchers
    • SERN
    • Find a PhD Supervisor
  • International
    • Queen's and Malaysia
  • Careers & Work Placements
    • Alumni
    • Placements
    • Shadowing Opportunities
    • Global Partnerships
  • Discover
    • Research Facilities
    • Teaching Facilities
    • History
  • Connect
    • Staff Directory
    • Key Contacts
    • Student Stories
    • Gender Equality Office
    • Staff Sharepoint Site
    • COVID-19 (Coronavirus)
  • News
  • Home
  • Study
    • Postgraduate Taught
    • Postgraduate Research
    • Centre for Biomedical Sciences Education
    • Intercalated Degrees
    • Clinical Academic Training
  • Research
    • Research in the School of Medicine, Dentistry and Biomedical Sciences
    • Meet our Researchers
    • SERN
    • Find a PhD Supervisor
  • International
    • Queen's and Malaysia
  • Careers & Work Placements
    • Alumni
    • Placements
    • Shadowing Opportunities
    • Global Partnerships
  • Discover
    • Research Facilities
    • Teaching Facilities
    • History
  • Connect
    • Staff Directory
    • Key Contacts
    • Student Stories
    • Gender Equality Office
    • Staff Sharepoint Site
    • COVID-19 (Coronavirus)
  • News
  • Our
  • Our
  • Our
In This Section

  • Home
  • School of Medicine, Dentistry and Biomedical Sciences
  • News

News

Queen’s and Ipsen enter partnership for innovative first-in-class cancer therapy

23 November, 2021

Queen’s University of Belfast and the global biopharmaceutical company Ipsen have entered a collaboration and licensing agreement relating to Queen’s cutting-edge preclinical stage first-in-class FLIP inhibitor programme.

Research lab

The FLIP(i) programme is a cutting-edge drug discovery programme, supported by Wellcome. FLIP is a major apoptosis-regulatory protein that is frequently overexpressed in hematological and solid tumors (including colorectal, lung and pancreatic cancer). It has been implicated in the regulation of multiple aspects of programmed cell death and is of significant interest as a novel cancer therapeutic target.

Lead researcher Professor Dan Longley explains: "Resistance to current treatments for various types of cancer and leukaemias is a major clinical problem. Our work at Queen’s has demonstrated that FLIP is frequently highly expressed in certain cancers and leukaemias and that this can cause resistance to treatment leading to patient relapse. By targeting FLIP, we aim to overcome this resistance and improve outcomes for patients."

The programme first commenced over a decade ago when Professor Dan Longley and his team at Queen’s discovered a novel protein-protein interaction (PPI). Prior to this seminal work the PPI of FLIP-FADD was widely thought to be 'undruggable'. Through carrying out extensive research into the binding events, the team realised that there were significant differences in their binding modes and a completely new therapeutic opportunity was recognised. With the support of Wellcome, and advice from Domainex, a leading UK-based provider of medicine research services, the team at Queen’s have been able to find selective inhibitors of the FLIP-FADD PPI.

Commenting on the news Howard Mayer, EVP Head of R&D at Ipsen said, “This collaboration provides strong development synergies for Ipsen and the opportunity to target the apoptosis (cell death) pathway to develop innovative cancer therapies. We are delighted to be working with the team at Queen’s and we believe great partnerships create great possibilities.” 

The academic team at Queen’s, led by Professor Longley and Professor Tim Harrison have developed novel, small molecule FLIP inhibitors and used these to achieve pre-clinical proof of concept. The priority for the team is now to progress this programme towards clinical development.

Professor Longley commented: “Our work to date strongly supports the potential for FLIP inhibitors as therapeutic agents in multiple oncology settings. Our team is looking forward to partnering with Ipsen’s clinical and development experts, harnessing their global knowledge, expertise and networks to advance this program and bring a FLIP inhibitor to people living with cancer around the world.” 

Professor Harrison added: “We are excited about the potential of the novel, first in class small molecule FLIP inhibitors we have been able to develop thanks to the support from Wellcome, and now are looking forward to working with Ipsen to move these molecules through the next stages of development, and ultimately into new treatments for patients.” 

Brian McCaul, Director of Innovation at Queen’s, commented:  “By working in collaboration with researchers, investors and industry partners, our commercialisation teams are here to translate invention into real world impact that makes a difference to people’s lives. The FLIP(i) program is an example of the exceptional innovation happening at Queen’s.”

Dr Lynsey Bilsland, Wellcome’s Innovations Lead for the FLIP(i) program, commented: “The FLIP inhibitor program is an excellent example of using novel ideas in drug discovery to try and improve cancer outcomes. We have high confidence in the teams at Ipsen and Queen’s in further developing this technology into the clinic.” 

Under the agreement Ipsen received a global exclusive licence to research, develop, manufacture, and commercialize FLIP inhibitors. 

Media

Media enquiries to comms.officer@qub.ac.uk

Share
Latest News
  • Queen's hosts 'Reflections on a Pandemic’ In Conversation event with UK Chief Medical Officers
    19 December, 2022
  • Breast, colorectal, oesophageal, stomach and head & neck cancer incidence and survival statistics NI
    14 December, 2022
  • DNA discovery may provide better and more targeted treatments for cancer
    2 December, 2022
  • Queen’s study plays key role in linking statin use with lowered risk of losing sight in later life
    10 November, 2022
  • CV6 Therapeutics to invest almost £8m in clinical trial for new anti-cancer drug
    3 November, 2022
Home
  • Home
  • Study
  • Research
  • International
  • Careers & Work Placements
  • Discover
  • Connect
  • News
Queen's University Belfast - Logo (small)
Contact Us

School of Medicine, Dentistry and Biomedical Sciences

Whitla Medical Building,
97 Lisburn Road,
Belfast, BT9 7BL

GET DIRECTIONS

Phone: +44 (0)2890 972215

Quick Links

  • Key Contacts
  • Careers & Work Placements
  • News and Events
  • Staff Directory
© Queen's University Belfast 2023
Privacy and cookies
Website accessibility
Freedom of information
Modern slavery statement
Equality, Diversity and Inclusion
Manage cookies